Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to prevent dangerous blood pressure drops during dialysis

NCT ID NCT03171545

Knowledge-focused Sponsor: University of Michigan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether teaching dialysis staff and providing support to patients could reduce episodes of dangerously low blood pressure during treatment. Over 1,400 patients across multiple clinics took part. The goal was to make dialysis sessions safer and more stable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this approach could lead to safer dialysis sessions and fewer complications for kidney failure patients.
What could go wrong
This is a completed study testing behavioral changes, not a new drug or device. Results may not apply to all dialysis centers or patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,431 people

The number who actually took part.

Started

Jan 2023

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Selection is at both the clinic level and individual patient level. Clinic Inclusion Criteria: * outpatient hemodialysis facilities * at least 70 adult (\>21 years old) patients to guarantee sample size Clinic Exclusion Criteria: * facilities involved in another study * facilities in immediate jeopardy * facilities with 1-star quality ratings * facilities designated as COVID-19 isolation facilities Individual Patient Exclusion Criteria: * individual patients who are currently incarcerated * individual patients who have poor cognition or cognitive impairment * individual patients unable to comprehend the patient information sheet due to lack of facility in English or Spanish * individual patients who have opted out of data collection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder chronic kidney disease end stage renal failure hypotensive disorder kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases End-stage renal disease Hypotension Kidney failure Patient safety

Contacts and locations

Locations

  • Fresenius Kidney Care University Of Michigan - Ann Arbor

    Ann Arbor, Michigan, 48104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.